DLBCL - FOI Response Register

1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Nil

2. Of these patients, how many commenced treatment at your trust within the last 6 months?

N/A

3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)

R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)

(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)

R-GemOX (rituximab, gemcitabine and Oxaliplatin)

Axicabtagene ciloleucel  

Tisagenlecleucel

Epcoritamab

Loncastuximab tesirine

Glofitamab

Any other SACT

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Given the small numbers of patients involved; the specific and sensitive nature of the health conditions referred to; the size of Shetland’s population; the specific treatments; and the short timeframe, NHS Shetland considers that providing any answers to question 3 carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

4.  In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

R-GemOX (rituximab, gemcitabine and Oxaliplatin)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatments  

Nil to all

5. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)?

Nil

6. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatment

Nil to all